3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine | 1204483-18-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine
• 英文别名: N-{3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropyl}acetamide；N-[4-(4-{[6-(propan-2-yloxy)pyridin-3-yl]oxy}phenyl)butan-2-yl]acetamide；N-[4-[4-(6-propan-2-yloxypyridin-3-yl)oxyphenyl]butan-2-yl]acetamide
• CAS: 1204483-18-0
• 化学式: C₂₀H₂₆N₂O₃
• 分子量: 342.438
• InChiKey: CHLNWUAMDPEDES-UHFFFAOYSA-N

物化性质

• 沸点：
  515.1±50.0 °C(Predicted)
• 密度：
  1.084±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine 在 Chiralcel OJ-H/58 作用下， 以 甲醇 、 乙醇 、 正庚烷 为溶剂， 生成 (S)-3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine 、 (R)-3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF
  [FR] COMPOSÉS HÉTÉROCYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION, MÉDICAMENTS COMPRENANT LESDITS COMPOSÉS ET LEUR UTILISATION

  摘要：

  公开号：

  WO2010003624A3
• 作为产物：
  描述：

  2-氯-5-羟基吡啶 在 吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 10% palladium on activated carbon 、 氢气 、 sodium hydride 、 potassium carbonate 、 一水合肼 、 三乙胺 、 copper(II) oxide 作用下， 以 N-甲基吡咯烷酮 、 乙醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 20.0~150.0 ℃ 、300.01 kPa 条件下， 反应 20.0h， 生成 3-[4-(6-isopropoxypyridin-3-yloxy)phenyl]-1-methylpropylamine
  参考文献：
  名称：

  Identification and Synthesis of Novel Inhibitors of Acetyl-CoA Carboxylase with in Vitro and in Vivo Efficacy on Fat Oxidation

  摘要：

  Acetyl CoA carboxylase isoforms 1 and 2 (ACC1/2) are key enzymes of fat utilization and their inhibition is considered to improve aspects of the metabolic syndrome. To identify pharmacological inhibitors of ACC1/2, a high throughput screen was performed which resulted in the identification of the lead compound 3 (Gargazanli, G.; Lardenois, P.; Frost, J.; George, P. Patent WO9855474 A1, 1998) as a moderate selective ACC2 inhibitor. Optimization of 3 led to 4m (Zoller, G.; Schmoll, D.; Mueller, M.; Haschke, G.; Focken, I. Patent WO2010003624 A2, 2010) as a submicromolar dual ACC1/2 inhibitor of the rat and human isoforms. 4m possessed favorable pharmacokinetic parameters. This compound stimulated fat oxidation in vivo and reduced plasma triglyceride levels in a rodent model after subchronic administration. 4m is a suitable tool compound for the elucidation of the pharmacological potential of ACC1/2 inhibition.

  DOI：

  10.1021/jm101179e

文献信息

• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF
  申请人：Zoller Gerhard

  公开号：US20110183998A1

  公开（公告）日：2011-07-28

  Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.

  杂环衍生物、其制备方法、包含这些化合物的药物和其用途。本发明涉及式I中的化合物，其中基团R1、R2、R3、R4、W、A、B、D、E、G、L、M、R、T和Y具有所述的含义，并且其生理上可耐受的盐。该化合物适用于例如代谢综合征、胰岛素抵抗、肥胖和糖尿病的治疗。
• NOVEL ALKYLENE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP3059225A1

  公开（公告）日：2016-08-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。 此外，本发明的目的是提供包含该化合物的药物组合物。 式（I）化合物：其中 R1 是取代或未取代的融合芳香杂环等，环 A 是取代或未取代的非芳香碳环等、 -L1-是-O-(CR6R7)m-等，-L2-是-O-(CR6R7)n-等，每个 R6 和 R7 独立地是氢、卤素等，R2 是取代或未取代的烷基，R3 是氢或取代或未取代的烷基，R4 是取代或未取代的烷基羰基等。
• ACC2 INHIBITORS
  申请人：Shionogi & Co., Ltd.

  公开号：EP3670496A2

  公开（公告）日：2020-06-24

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L1- is -O-(CR6R7)m- etc., -L2- is -O-(CR6R7)n- etc., each R6 and R7 are independently hydrogen, halogen etc., R2 is substituted or unsubstituted alkyl, R3 is hydrogen or substituted or unsubstituted alkyl, R4 is substituted or unsubstituted alkylcarbonyl etc..

  本发明的目的是提供具有 ACC2 抑制活性的新型化合物。此外，本发明的目的是提供一种包含该化合物的药物组合物。 式(I)的化合物： 其中 R1 是取代或未取代的融合芳香杂环等、 环 A 是取代或未取代的非芳香族碳环等、 -L1-是-O-(CR6R7)m-等、 -L2-是-O-(CR6R7)n-等、 每个 R6 和 R7 独立地是氢、卤素等、 R2 是取代或未取代的烷基、 R3 是氢或取代或未取代的烷基、 R4 是取代或未取代的烷基羰基等。
• 9-membered fused ring derivative
  申请人：Shionogi & Co., Ltd.

  公开号：US10233156B2

  公开（公告）日：2019-03-19

  The purpose of the present invention is to provide novel compounds having ACC2 selective inhibitory activity. In addition, the present invention provides a pharmaceutical composition comprising the compound. A compound of Formula: or its pharmaceutically acceptable salt, wherein, R1 is substituted or unsubstituted fused aromatic heterocyclyl represented by Formula: wherein, ring B is 5-membered ring, ring C is 6-membered ring; ring A is substituted or unsubstituted non-aromatic carbocycle or the like; —L1— is —O—(CR6R7)m— or the like; —L2— is —O—(CR6R7)n— or the like; each R6 is independently hydrogen or the like; each R7 is independently hydrogen or the like; each m is independently an integer of 0, 1, 2 or 3; each n is independently an integer of 1, 2 or 3; R2 is substituted or unsubstituted alkyl; R3 is hydrogen or substituted or unsubstituted alkyl; R4 is substituted or unsubstituted alkylcarbonyl or the like.

  本发明的目的是提供具有 ACC2 选择性抑制活性的新型化合物。此外，本发明还提供了一种包含该化合物的药物组合物。 式的化合物： 或其药学上可接受的盐、 其中，R1 是由式表示的取代或未取代的融合芳香杂环基： 其中 环 B 是 5 元环，环 C 是 6 元环； 环 A 是取代或未取代的非芳香族碳环或类似物； -L1-是-O-(CR6R7)m-或类似物； -L2-是-O-(CR6R7)n-或类似物； 每个 R6 独立地为氢或类似物 每个 R7 独立地为氢或类似物； 每个 m 独立地为 0、1、2 或 3 的整数 每个 n 独立地为 1、2 或 3 的整数； R2 是取代或未取代的烷基； R3 是氢或取代或未取代的烷基； R4 是取代或未取代的烷基羰基或类似物。